

z is 1.

Conclusion

Applicants elected the species, Compound (V) and affirm their right to file one or more divisional applications with respect to any of the non-elected subject matter.

If a telephone interview would be of assistance in advancing prosecution of this application, Applicant's agent invites the Examiner to contact him at the number provided below.

Respectfully submitted,




Dated: October 22, 2001

Peter L. Dolan, Ph.D.
Agent for Applicants
Registration No. 46,307
(302)992-4528

Appendix 1
Marked-Up Version of Rewritten Claims

6. (Amended) The method of Claim 4 wherein the localization step comprises the step of localizing a compound of the formula (I) at the thrombus wherein Q is of the formula (II),



(II)

or a pharmaceutically acceptable salt or prodrug form thereof wherein:

R^{31} is a C6-C14 saturated, partially saturated, or aromatic carbocyclic ring system substituted with 0-4 R^{10} or R^{10a} ;

R^{32} is selected from:

- C(=O)-;
- C(=S)-
- S(=O)2-;
- S(=O)-;
- P(=Z)(ZR¹³)-;

Z is S or O;

n'' and n' are independently 0-2;

R^1 and R^{22} are independently selected from the following groups:

hydrogen,

C_1-C_8 alkyl substituted with 0-2 R^{11} ;

C_2-C_8 alkenyl substituted with 0-2 R^{11} ;

C_2-C_8 alkynyl substituted with 0-2 R^{11} ;

C_3-C_{10} cycloalkyl substituted with 0-2 R^{11} ;

aryl substituted with 0-2 R^{12} ;

a 5-10-membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O, said heterocyclic ring being substituted with 0-2 R^{12} ;

$=O$, F, Cl, Br, I, $-CF_3$, $-CN$, $-CO_2R^{13}$, $-C(=O)R^{13}$, $-C(=O)N(R^{13})_2$, $-CHO$, $-CH_2OR^{13}$, $-OC(=O)R^{13}$, $-OC(=O)OR^{13a}$, $-OR^{13}$, $-OC(=O)N(R^{13})_2$, $-NR^{13}C(=O)R^{13}$, $-NR^{14}C(=O)OR^{13a}$, $-NR^{13}C(=O)N(R^{13})_2$, $-NR^{14}SO_2N(R^{13})_2$, $-NR^{14}SO_2R^{13a}$, $-SO_3H$, $-SO_2R^{13a}$, $-SR^{13}$, $-S(=O)R^{13a}$, $-SO_2N(R^{13})_2$, $-N(R^{13})_2$, $-NHC(=NH)NHR^{13}$, $-C(=NH)NHR^{13}$, $=NOR^{13}$, NO_2 , $-C(=O)NHOR^{13}$, $-C(=O)NHNR^{13}R^{13a}$, $-OCH_2CO_2H$, 2-(1-morpholino)ethoxy;

R^1 and R^{21} can alternatively join to form a 3-7 membered carbocyclic ring substituted with 0-2 R^{12} ;

when n' is 2, R^1 or R^{21} can alternatively be taken together with R^1 or R^{21} on an adjacent carbon atom to form a direct bond, thereby to form a double or triple bond between said carbon atoms;

R^{22} and R^{23} can alternatively join to form a 3-7 membered carbocyclic ring substituted with 0-2 R^{12} ;

when n'' is 2, R^{22} or R^{23} can alternatively be taken together with R^{22} or R^{23} on an adjacent carbon atom to form a direct bond, thereby to form a double or triple bond between the adjacent carbon atoms;

R^1 and R^2 , where R^{21} is H, can alternatively join to form a 5-8 membered carbocyclic ring substituted with 0-2 R^{12} ;

R^{11} is selected from one or more of the following:

=O, F, Cl, Br, I, -CF₃, -CN, -CO₂R¹³, -C(=O)R¹³,
 $-C(=O)N(R^{13})_2$, -CHO, -CH₂OR¹³, -OC(=O)R¹³, -OC(=O)OR^{13a},
 $-OR^{13}$, -OC(=O)N(R¹³)₂, -NR¹³C(=O)R¹³, -NR¹⁴C(=O)OR^{13a},
 $-NR^{13}C(=O)N(R^{13})_2$, -NR¹⁴SO₂N(R¹³)₂, -NR¹⁴SO₂R^{13a}, -SO₃H,
 $-SO_2R^{13a}$, -SR¹³, -S(=O)R^{13a}, -SO₂N(R¹³)₂, -N(R¹³)₂,
 $-NHC(=NH)NHR^{13}$, -C(=NH)NHR¹³, =NOR¹³, NO₂, -C(=O)NHOR¹³,
 $-C(=O)NHR^{13}R^{13a}$, -OCH₂CO₂H, 2-(1-morpholino)ethoxy,

C₁-C₅ alkyl, C₂-C₄ alkenyl, C₃-C₆ cycloalkyl,
C₃-C₆ cycloalkylmethyl, C₂-C₆ alkoxyalkyl,
C₃-C₆ cycloalkoxy, C₁-C₄ alkyl (alkyl being substituted with 1-5 groups selected independently from: -NR¹³R¹⁴, -CF₃, NO₂, -SO₂R^{13a}, or -S(=O)R^{13a}),

aryl substituted with 0-2 R^{12} ,

a 5-10-membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O, said heterocyclic ring being substituted with 0-2 R^{12} ;

R^{12} is selected from one or more of the following:

phenyl, benzyl, phenethyl, phenoxy, benzyloxy, halogen, hydroxy, nitro, cyano, C1-C5 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C7-C10 arylalkyl, C1-C5 alkoxy, -CO₂R¹³, -C(=O)NHOR^{13a}, -C(=O)NHN(R¹³)₂, =NOR¹³, -B(R³⁴)(R³⁵), C3-C6 cycloalkoxy, -OC(=O)R¹³, -C(=O)R¹³, -OC(=O)OR^{13a}, -OR¹³, -(C1-C4 alkyl)-OR¹³, -N(R¹³)₂, -OC(=O)N(R¹³)₂, -NR¹³C(=O)R¹³, -NR¹³C(=O)OR^{13a}, -NR¹³C(=O)N(R¹³)₂, -NR¹³SO₂N(R¹³)₂, -NR¹³SO₂R^{13a}, -SO₃H, -SO₂R^{13a}, -S(=O)R^{13a}, -SR¹³, -SO₂N(R¹³)₂, C2-C6 alkoxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -OCH₂CO₂H, 2-(1-morpholino)ethoxy, C1-C4 alkyl (alkyl being substituted with -N(R¹³)₂, -CF₃, NO₂, or -S(=O)R^{13a});

R¹³ is selected independently from: H, C1-C10 alkyl, C3-C10 cycloalkyl, C4-C12 alkylcycloalkyl, aryl, -(C1-C10 alkyl)aryl, or C3-C10 alkoxyalkyl;

R^{13a} is C1-C10 alkyl, C3-C10 cycloalkyl, C4-C12 alkylcycloalkyl, aryl, -(C1-C10 alkyl)aryl, or C3-C10 alkoxyalkyl;

when two R¹³ groups are bonded to a single N, said R¹³ groups may alternatively be taken together to form -(CH₂)₂₋₅₋ or -(CH₂)O(CH₂)-;

R¹⁴ is OH, H, C1-C4 alkyl, or benzyl;

R²¹ and R²³ are independently selected from:

hydrogen;
 C1-C4 alkyl, optionally substituted with 1-6
 halogen;
 benzyl;

R² is H or C1-C8 alkyl;

R¹⁰ and R^{10a} are selected independently from one or
 more of the following:

phenyl, benzyl, phenethyl, phenoxy, benzyloxy,
 halogen, hydroxy, nitro, cyano, C1-C5 alkyl,
 C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl,
 C7-C10 arylalkyl, C1-C5 alkoxy, -CO₂R¹³, -C(=O)N(R¹³)₂,
 -C(=O)NHOR^{13a}, -C(=O)NHN(R¹³)₂, =NOR¹³, -B(R³⁴)(R³⁵),
 C3-C6 cycloalkoxy, -OC(=O)R¹³, -C(=O)R¹³, -OC(=O)OR^{13a},
 -OR¹³, -(C1-C4 alkyl)-OR¹³, -N(R¹³)₂, -OC(=O)N(R¹³)₂,
 -NR¹³C(=O)R¹³, -NR¹³C(=O)OR^{13a}, -NR¹³C(=O)N(R¹³)₂,
 -NR¹³SO₂N(R¹³)₂, -NR¹³SO₂R^{13a}, -SO₃H, -SO₂R^{13a},
 -S(=O)R^{13a}, -SR¹³, -SO₂N(R¹³)₂, C2-C6 alkoxyalkyl,
 methylenedioxy, ethylenedioxy, C1-C4 haloalkyl (including
 -C_vF_w where v = 1 to 3 and w = 1 to (2v+1)),
 C1-C4 haloalkoxy, C1-C4 alkylcarbonyloxy,
 C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, -OCH₂CO₂H,
 2-(1-morpholino)ethoxy, C1-C4 alkyl (alkyl being
 substituted with -N(R¹³)₂, -CF₃, NO₂, or -S(=O)R^{13a});

J is 3-aminopropionic acid or an L-isomer or
 D-isomer amino acid of structure -N(R³)C(R⁴)(R⁵)C(=O)-,
 wherein:

R³ is H or C1-C8 alkyl;

R⁴ is H or C1-C3 alkyl;

R⁵ is selected from:

hydrogen;

C₁-C₈ alkyl substituted with 0-2 R¹¹;

C₂-C₈ alkenyl substituted with 0-2 R¹¹;

C₂-C₈ alkynyl substituted with 0-2 R¹¹;

C₃-C₁₀ cycloalkyl substituted with 0-2 R¹¹;


aryl substituted with 0-2 R¹²;

a 5-10-membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, or O, said heterocyclic ring being substituted with 0-2 R¹²;

=O, F, Cl, Br, I, -CF₃, -CN, -CO₂R¹³, -C(=O)R¹³, -C(=O)N(R¹³)₂, -CHO, -CH₂OR¹³, -OC(=O)R¹³, -OC(=O)OR^{13a}, -OR¹³, -OC(=O)N(R¹³)₂, -NR¹³C(=O)R¹³, -NR¹⁴C(=O)OR^{13a}, -NR¹³C(=O)N(R¹³)₂, -NR¹⁴SO₂N(R¹³)₂, -NR¹⁴SO₂R^{13a}, -SO₃H, -SO₂R^{13a}, -SR¹³, -S(=O)R^{13a}, -SO₂N(R¹³)₂, -N(R¹³)₂, -NHC(=NH)NHR¹³, -C(=NH)NHR¹³, =NOR¹³, NO₂, -C(=O)NHOR¹³, -C(=O)NHNHR¹³R^{13a}, =NOR¹³, -B(R³⁴)(R³⁵), -OCH₂CO₂H, 2-(1-morpholino)ethoxy, -SC(=NH)NHR¹³, N₃, -Si(CH₃)₃


(C₁-C₅ alkyl)NHR¹⁶;

-(C₀-C₆ alkyl)X;



, where q is


independently 0, 1;



$-(CH_2)_m S(O)p' (CH_2)_2 X$, where $m = 1, 2$ and $p' = 0-2$;

~~wherein X is defined below~~; and

R^3 and R^4 may also be taken together to form



R^3 and R^5 can alternatively be taken together to form $-(CH_2)_t-$ or $-CH_2 S(O)p' C(CH_3)_2-$, where $t = 2-4$ and $p' = 0-2$; or

R^4 and R^5 can alternatively be taken together to form $-(CH_2)_u-$, where $u = 2-5$;

R^{16} is selected from:

an amine protecting group;

1-2 amino acids;

1-2 amino acids substituted with an amine protecting group;


K is a D-isomer or L-isomer amino acid of structure

$-\underline{N}(R^6)CH(R^7)C(=O)-$, wherein:

R^6 is H or C1-C8 alkyl;


R^7 is selected from:

$-(C1-C7$ alkyl) X ;




, wherein each q is

independently 0-2 and substitution on the phenyl is at the 3 or 4 position;



, wherein each q is


independently 0-2 and substitution on the cyclohexyl is at the 3 or 4 position;



$-(CH2)mO-(C1-C4$ alkyl) $-X$, where m = 1 or 2;

$-(CH2)mS(O)p'-(C1-C4$ alkyl) $-X$, where m = 1 or and p' = 0-2; and


X is selected from:




$-\text{N}(\text{R}^{13})\text{R}^{13}; \quad -\text{C}(\text{=NH})(\text{NH}_2); \quad -\text{SC}(\text{=NH})\text{---NH}_2;$

$-\text{NH---C}(\text{=NH})(\text{NHCN}); \quad -\text{NH---C}(\text{=NCN})(\text{NH}_2); \quad -\text{NH---C}(\text{=N---OR}^{13})(\text{NH}_2);$

R^6 and R^7 can alternatively be taken together to form



independently 1 or 2 and wherein $n = 0$ or 1 and X is $-\text{NH}_2$




or

L is $-\text{Y}(\text{CH}_2)_v\text{C}(\text{=O})-$, wherein:

Y is NH , $\text{N}(\text{C}_1\text{---C}_3\text{ alkyl})$, O , or S ; and $v = 1$ or 2 ;

M is a D-isomer or L-isomer amino acid of structure



q' is 0-2;

R^{17} is H , $\text{C}_1\text{---C}_3$ alkyl;

R^8 is selected from:

-CO₂R¹³, -SO₃R¹³, -SO₂NHR¹⁴, -B(R³⁴)(R³⁵), -NHSO₂CF₃,
-CONHNHSO₂CF₃, -PO(OR¹³)₂, -PO(OR¹³)R¹³,
-SO₂NH-heteroaryl (said heteroaryl being 5-10-membered
and having 1-4 heteroatoms selected independently from N,
S, or O), -SO₂NH-heteroaryl (said heteroaryl being
5-10-membered and having 1-4 heteroatoms selected
independently from N, S, or O), -SO₂NHCOR¹³,
-CONHSO₂R^{13a}, -CH₂CONHSO₂R^{13a}, -NHSO₂NHCOR^{13a}, -
NHCONHSO₂R^{13a}, -SO₂NHCONHR¹³;

R³⁴ and R³⁵ are independently selected from:

-OH,

-F,

-N(R¹³)₂, or

C₁-C₈-alkoxy;

R³⁴ and R³⁵ can alternatively be taken together
form:

a cyclic boron ester where said chain or ring
contains from 2 to 20 carbon atoms and, optionally, 1-4
heteroatoms independently selected from N, S, or O;

a divalent cyclic boron amide where said chain or
ring contains from 2 to 20 carbon atoms and, optionally,
1-4 heteroatoms independently selected from N, S, or O;

a cyclic boron amide-ester where said chain or ring
contains from 2 to 20 carbon atoms and, optionally, 1-4
heteroatoms independently selected from N, S, or O.